Persistent infections in chronic Chagas'disease patients treated with anti-Trypanosoma cruzi nitroderivatives
Rev. Inst. Med. Trop. Säo Paulo
; 42(3): 157-61, May-Jun. 2000. ilus, tab
Article
em En
| LILACS
| ID: lil-262695
Biblioteca responsável:
BR1.1
ABSTRACT
We used a molecular method and demonstrated that treatment of the chronic human Trypanosoma cruzi infections with nitroderivatives did not lead to parasitological cure. Seventeen treated and 17 untreated chronic Chagas' disease patients, with at least two out of three positive serologic assays for the infection, and 17 control subjects formed the study groups. PCR assays with nested sets of T. cruzi DNA primers monitored the efficacy of treatment. The amplification products were hybridized to their complementary internal sequences. Untreated and treated Chagas' disease patients yielded PCR amplification products with T. cruzi nuclear DNA primers. Competitive PCR was conducted to determine the quantity of parasites in the blood and revealed < 1 to 75 T. cruzi/ml in untreated (means 25.83 +/- 26.32) and < 1 to 36 T. cruzi/ml in treated (means 6.45 +/- 9.28) Chagas' disease patients. The difference between the means was not statistically significant. These findings reveal a need for precise definition of the role of treatment of chronic Chagas'disease patients with nitrofuran and nitroimidazole compounds.
Texto completo:
1
Base de dados:
LILACS
Assunto principal:
Tripanossomicidas
/
Trypanosoma cruzi
/
Doença de Chagas
/
Nifurtimox
/
Nitroimidazóis
Limite:
Humans
/
Male
Idioma:
En
Ano de publicação:
2000
Tipo de documento:
Article